Introduction

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 8, 2013, Pages 525-526

  Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAS RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR;

HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; EDITORIAL; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84880975803     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12134     Document Type: Review

References (8)

1. 2R as a therapeutic target in hypertension in men and women: What we know and what we still need to find out. Clin. Exp. Pharmacol. Physiol. 2013; 40: 542-50.
2. 2 receptors in natriuresis: Intrarenal mechanisms and therapeutic potential. Clin. Exp. Pharmacol. Physiol. 2013; 40: 527-34.
3. Sumners C, Horiuchi M, Widdop R, McCarthy C, Unger T, Steckelings U. The protective arms of the renin-angiotensin system in neurological disease. Clin. Exp. Pharmacol. Physiol. 2013; 40: 580-8.
4. McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL. Brain and retinal microglia in health and disease: An unrecognized target of the renin-angiotensin system. Clin. Exp. Pharmacol. Physiol. 2013; 40: 571-9.
5. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: Where does ACE2 fit in? Clin. Exp. Pharmacol. Physiol. 2013; 40: 551-9.
6. Douglas RG, Ehlers MR, Sturrock ED. The anti-fibrotic peptide Ac-SDKP. Opportunities for ACE inhibitor design. Clin. Exp. Pharmacol. Physiol. 2013; 40: 535-41.
7. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. N-Domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: Angiotensin-(1-7) and keto-ACE. Hypertension 1998; 31: 912-7.
8. Campbell DJ. Do intravenous and subcutaneous angiotensin II administration increase blood pressure by different mechanisms? Clin. Exp. Pharmacol. Physiol. 2013; 40: 560-70.